Description
Semax 5 mg – Advanced Peptide for Cognitive Function & Neuroprotection
Composition: 5 mg Semax (lyophilized peptide powder)
Category: Peptide
Form: Vial with freeze-dried powder
Administration: Subcutaneous injection after reconstitution with bacteriostatic water
What is Semax?
Semax is a synthetic heptapeptide originally developed by the Russian Academy of Sciences for use in neurological and cognitive research.
It is an ACTH-derived peptide analogue that has been extensively studied for its neuroprotective, nootropic, and neurorestorative properties.
Semax influences the expression of Brain-Derived Neurotrophic Factor (BDNF), modulates dopaminergic and serotonergic systems, and supports neuronal resilience under stress conditions.
➡️ Ideal for researchers exploring next-generation neuroregulatory compounds.
Key Research Findings
Cognitive Enhancement: May improve learning capacity, concentration, and short-term memory.
Neuroprotection: Reduces oxidative stress and supports nerve cell regeneration.
Mood & Stress Regulation: Modulates neurotransmitters linked to motivation and emotional stability.
Increased BDNF Expression: Promotes synaptic plasticity and neuronal adaptability.
Dosage & Application
Reconstitute with bacteriostatic water before use.
Typical research range: 250–1000 µg per application, up to 2 times daily, administered subcutaneously.
Store the reconstituted solution refrigerated and use within 20–30 days.
Storage Instructions
-
Store at 2–8 °C (36–46 °F)
-
Protect from light and moisture
-
Do not freeze
-
Avoid repeated temperature fluctuations
Why Choose Semax?
Semax is one of the most extensively studied nootropic peptides in Eastern Europe, known for its broad neuroprotective profile and excellent safety record.
Its ability to enhance BDNF expression and promote cognitive resilience makes it one of the most valuable tools in neuroscience research.
Order Semax 5 mg and unlock the full potential of this peptide in cognitive and neuroprotective studies.





Reviews
There are no reviews yet.